Friday, Dec. 14, 5 to 7 p.m.
Poster presentation: "Gene expression by standardized quantitative RT-PCR
in the special histologic subtypes of estrogen receptor positive invasive
"Presenter: Frederick L. Baehner, M.D.
Poster presentation: "Evaluation of practice patterns in the treatment of
node-negative, hormone-receptor positive breast cancer patients with the
use of the Oncotype DX assay at the University of Pennsylvania.
"Presenter: Christopher Erb, M.D., Ph.D.
Saturday, Dec. 15, 4 to 4:15 p.m.
Oral presentation: "Prognostic utility of the 21-gene assay
compared with Adjuvant! in hormone receptor (HR) positive operable breast
cancer with 0-3 positive axillary nodes treated with adjuvant
chemohormonal therapy (CHT): an analysis of intergroup trial
"Presenter: Lori J. Goldstein, M.D.
Saturday, Dec. 15, 5 to 7 p.m.
Poster presentation: "Estrogen receptor and breast cancer survival in a
Kaiser Permanente population-based study: comparison of quantitative
reverse transcriptase polymerase chain reaction and
"Presenter: Laurel A. Habel, M.D.
About Oncotype DX(R)
Oncotype DX is the first diagnostic multi-gene expression test
commercially available that has clinical evidence validating its ability to
predict the likelihood of breast cancer recurrence, the likelihood of
breast cancer survival and the likelihood of chemotherapy benefit. Oncotype
DX has been extensively evaluated in multiple independent studies involving
more than 3,300 breast cancer patients, including a large validation study
published in The New England Journal of Medicine and a chemotherapy benefit
study published in the Journal of Clinical Oncology. To date, nearly 7,000
physicians have ordered more than 40,000 tests, a
|SOURCE Genomic Health, Inc.|
Copyright©2007 PR Newswire.
All rights reserved